ReviewSynthetic and systems biotechnology2027
Genetic engineering of cyanophages for harmful cyanobacterial bloom treatment-A mini review.
Review in Synthetic and systems biotechnology, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Harmful cyanobacterial blooms (HCBs) are a prominent worldwide environmental concern. Proliferation of HCBs outpaces the development of mitigation and management technologies. Recently, cyanophages began to emerge as a potential abundant resource that can be harnessed for target-specific HCB treatment. However, there exist two major technical barriers in applying cyanophage-based treatment to HCB mitigation: host specificity and lysogenic life cycle. This minireview attempts to parse documented studies that developed or applied genetic engineering approaches or technologies to tackle the barriers through expanding host range and bypassing or abolishing the lysogenic life stage. We summarized representative technical approaches that may be extrapolated from bacteriophage to cyanophage, discussed genes and pathways that regulate host binding and infection or determine the switch between lytic and lysogenic lifecycles, identified existing knowledge and technological gaps and challenges, and proposed some attainable solutions and future perspectives for this fast-growing field of engineered cyanophage-mediated HCB remediation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.